Safety Shot launching clinical trial to measure effect of its drink on blood alcohol levels
Safety Shot Inc.'s stock (SHOT) was down 5% in in premarket trading on Friday after the company said it started a clinical trial to measure the effects of its Safety Shot drink on blood and breath alcohol. The product is designed as a nutraceutical functional beverage that accelerates the body's breakdown of alcohol while aiding in recovery and rehydration, the company said. The study includes a double-blinded placebo-controlled test in 36 participants to measure the amount of alcohol in the blood and breath, together with indices of alcohol effects. The company said it plans to launch business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars in the first quarter.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-24-23 0859ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: All Eyes on Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?